Loading...
Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
Keegan, Helen Mc Inerney, Jamie Pilkington, Loretto Gronn, Petter Silva, Ivan Karlsen, Frank Bolger, Noel Logan, Catriona Furuberg, Liv O'Leary, John
Keegan, Helen
Mc Inerney, Jamie
Pilkington, Loretto
Gronn, Petter
Silva, Ivan
Karlsen, Frank
Bolger, Noel
Logan, Catriona
Furuberg, Liv
O'Leary, John
Advisors
Editors
Other Contributors
Date
2012-02-01T10:58:04Z
Date Submitted
Keywords
Other Subjects
Subject Mesh
Cervical Intraepithelial Neoplasia/diagnosis/virology
Cervix Uteri/*virology
DNA, Viral/*analysis
Female
Human papillomavirus 16/genetics/isolation & purification
Human papillomavirus 18/genetics/isolation & purification
Humans
Mass Screening/methods
Oncogene Proteins, Viral/genetics/*metabolism
Papillomaviridae/classification/genetics/*isolation & purification
Papillomavirus E7 Proteins/genetics/*metabolism
Papillomavirus Infections/diagnosis/virology
Polymerase Chain Reaction/methods
RNA, Messenger/genetics/*metabolism
RNA, Viral/*analysis/genetics/metabolism
Sensitivity and Specificity
Viral Load
Cervix Uteri/*virology
DNA, Viral/*analysis
Female
Human papillomavirus 16/genetics/isolation & purification
Human papillomavirus 18/genetics/isolation & purification
Humans
Mass Screening/methods
Oncogene Proteins, Viral/genetics/*metabolism
Papillomaviridae/classification/genetics/*isolation & purification
Papillomavirus E7 Proteins/genetics/*metabolism
Papillomavirus Infections/diagnosis/virology
Polymerase Chain Reaction/methods
RNA, Messenger/genetics/*metabolism
RNA, Viral/*analysis/genetics/metabolism
Sensitivity and Specificity
Viral Load
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
Human papillomavirus (HPV) testing using molecular methods in liquid based cytology (LBC) specimens may be useful as an adjunct to cervical screening by cytology. We compared the positivity rate of the commercially available HPV DNA method hybrid capture 2 (hc2) and the commercially available E6/E7 mRNA method PreTect HPV-Proofer in cytological specimens (n=299). LBC specimens collected (n=299) represented the following cervical cytological disease categories: Normal (n=60), borderline nuclear abnormalities (BNA) (n=34), CIN1 (n=121), CIN2 (n=60), CIN3 (n=24). Overall, 69% (205/299) of the cases were positive by hc2 and 38% (112/299) of the cases were positive by PreTect HPV-Proofer. Concordance rates between the two tests were highest in the high-grade cytology cases (CIN2: 67% and CIN3: 83%) and the normal cytology cases (88%) and lowest in the BNA and CIN1 categories (56% and 52%). HPV DNA viral load analyses were carried out on HPV16 (n=55), HPV18 (n=9) and HPV33 (n=13) samples that were positive by PreTect HPV-Proofer. The sensitivity and specificity of PreTect HPV-Proofer and the hc2 DNA test for the detection of high-grade cytology (i.e. CIN2+) were 71.4% and 75.8% vs 100% and 43.7%, respectively. The relatively low detection rate observed by PreTect HPV-Proofer in the whole range of cytological positive cases, combined with a relatively higher specificity and PPV, suggests that PreTect HPV-Proofer may be more useful than hc2 for triage and in predicting high-grade disease.
Language
eng
ISSN
0166-0934 (Print)
0166-0934 (Linking)
0166-0934 (Linking)
eISSN
ISBN
DOI
10.1016/j.jviromet.2008.09.027
PMID
18955086